NCT00421395View on ClinicalTrials.gov

Safety Study of NHL With 90Y-hLL2 IgG

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
NHLB-cell NHLNon-Hodgkins Lymphoma
Interventions
BIOLOGICAL

90Y-hLL2

weekly dosing for either 2 or 3 weeks

Trial Locations (5)

37075

Klinikum der Georg-August-Universitat Gottingen, Göttingen

44035

Research Unit 463 INSERM, Nantes

59037

Service des Maladies du Sang, Lille

01307

University Hospital Dresden, Dresden

D-66421

Universitatsklinikum University of Saarland, Homburg/Saar

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY